CervoMed's Neflamapimod Phase 2a Biomarker Data in nfvPPA Selected for Late-Breaking ISFTD Presentation
核心洞察
CervoMed will present 12-week plasma biomarker results for neflamapimod in nonfluent variant primary progressive aphasia (搜索) at the ISFTD Annual Meeting in October 2026.
The late-breaking oral presentation will report neurofilament light chain (搜索) and glial fibrillary acidic protein (搜索) data from at least 22 of the trial's 25 enrolled participants.
The Phase 2a trial, conducted at academic medical centers in the U.S. and U.K., was designed to assess safety, pharmacokinetics, and clinical effects of the oral p38 MAP kinase inhibitor.
CervoMed Inc. (NASDAQ: CRVO) announced that initial biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (搜索) (nfvPPA) have been accepted for a late-breaking oral presentation at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting, to be held in Philadelphia, Pennsylvania, from October 8-11, 2026.
The presentation, scheduled for Sunday, October 11, 2026, from 8:30 a.m. to 10:30 a.m. ET in the Plenary 6 (Hot Topics) session, will highlight 12-week data for two plasma biomarkers — neurofilament light chain (搜索) (NfL) and glial fibrillary acidic protein (搜索) (GFAP) — from at least 22 study participants. The abstract on which the acceptance was based described 12-week biomarker data from the trial's first eight participants.
Trial Design and Enrollment
CervoMed recently completed enrollment in the Phase 2a trial, which enrolled 25 participants and is being conducted at leading academic medical centers in the United States and United Kingdom. The trial was designed to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in participants with nfvPPA. The study is registered as NCT07033481.
Targeting p38 MAP Kinase in Tau-Driven Disease
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, described by the company as a key driver of neuroinflammation and synaptic dysfunction. According to CervoMed, peer-reviewed data demonstrate the relevance of p38α as a therapeutic target and support neflamapimod's potential to treat frontotemporal dementia (搜索) driven by tau (搜索) pathology.
By targeting the disease processes underlying degenerative disorders of the brain, the company states that neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. The drug candidate is currently in clinical development for dementia with Lewy bodies (搜索) (DLB), recovery after ischemic stroke (搜索), and nfvPPA.
An Unmet Need in Frontotemporal Dementia
nfvPPA is a type of frontotemporal dementia (搜索) (FTD) that gradually impairs the ability to express language, although patients retain understanding of word meaning. Early features include shorter phrases, pauses during speech, and difficulty pronouncing words, as well as challenges understanding long or complex sentences. In advanced nfvPPA, patients may stop speaking completely, and difficulties with planning, judgment, and movement can also occur.
nfvPPA is the type of FTD most commonly associated with tau (搜索) pathology. An estimated 10,000-15,000 people are living with nfvPPA in the U.S. and 15,000-20,000 in the E.U. There are currently no approved treatments for nfvPPA in either the United States or the European Union.
Regulatory and Development Context
Neflamapimod received Orphan Drug Designation from the U.S. FDA for FTD in 2024. Orphan Drug Designation is granted to investigational therapies addressing rare diseases affecting fewer than 200,000 people in the U.S., and provides benefits including assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees, and seven years of post-approval marketing exclusivity.
Beyond nfvPPA, CervoMed's recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without Alzheimer's disease co-pathology. In November 2025, the company announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and it is currently focused on identifying a strategic partner to advance the drug candidate into a Phase 3 trial in that indication. CervoMed also expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.